Inside Life Sciences

Inside Life Sciences

Issue 10
6862

Editor's Note

Welcome to the Spring 2020 edition of Inside Life Sciences.

Read more
15084

COVID-19: Pivoting to PPE manufacture – Key points to consider

Acute shortages of personal protective equipment (PPE) in the UK have been widely reported.

Read more
14789

COVID-19 and the Life Sciences Industry

The life sciences industry has, understandably, been at the forefront of discussions regarding the global COVID-19 pandemic, with evolving pressures and challenges on governments, the healthcare system and drug developers.

Read more
15076

Post-Brexit tariff regime begins to take shape

This week the UK's Department for International Trade set out the details of the UK's new tariff regime, the UK Global Tariff (UKGT).

Read more
14973

Inside Life Sciences – Patent and SPC Update

Life Sciences businesses have, no doubt, become used to the twists and turns surrounding the Unified Patent Court and Unitary Patent regime.

Read more
15252

High Court finds trade mark infringement through use of 'Merck'

In a long-running dispute between Merck KGaA (Merck Global) and US companies Merck Sharp & Dohme Corporation and Merck & Co (together Merck US), the High Court has decided that various uses of 'Merck' in the UK by Merck US, amount to trade mark infringement.

Read more
14969

Court of Appeal judgment in Flynn/Pfizer pricing case: where next for pharmaceutical pricing?

In March 2020, the Court of Appeal handed down its judgment in Competition and Markets Authority v Flynn Pharma Ltd & Ors [2020] EWCA Civ 339.

Read more
13616

"Pay-for-Delay"

The Court of Justice of the European Union (the "CJEU") has given guidance on 'pay for delay' agreements for the first time in its recent decision in Generics (UK) v Competition and Markets Authority.

Read more
15325

Patents Court rejects interim injunction in generic pharma dispute

The Patents Court has refused an interim injunction sought by Neurim (and Flynn Pharma claiming as exclusive licensee) against Mylan in relation to its planned launch of a generic competitor product to Circadin.

Read more
15401

Patents Court considers 'clearing the way' and disclosure of launch plans

In Teva v Chiesi, the Patents Court has considered the extent to which a generic pharmaceutical company should clear the way to market before launch and the implications for an infringement counterclaim brought by a patentee based on a threat by the generic to infringe, in circumstances where the generic has not yet obtained a marketing authorisation.

Read more

Previous Issues

Share

How can we help you?

How can we help you?

Subscribe: I'd like to keep in touch

If your enquiry is urgent please call +44 20 3321 7000

COVID-19 Enquiry

Please enter your first name
Please enter your last name
Please enter your enquiry
Please enter your email address
Please enter your phone number
Please select a contact method

I'm a client

Please enter your first name
Please enter your last name
Please enter your enquiry
Please enter an email address
Please enter your phone number
Please enter a value

I'm looking for advice

Please enter your first name
Please enter your last name
Please enter your enquiry
Please select a department
Please enter your email address
Please enter your phone number
Please select a contact method

Something else

Please enter your first name
Please enter your last name
Please enter your enquiry
Please enter your email address
Please enter your phone number
Please select your contact method of choice